Clinical Trials Logo

Clinical Trial Summary

The project aims to investigate the feasibility and acceptability of a blended face-to-face and smartphone intervention for distressing thoughts and experiences in people with schizophrenia spectrum disorders. A secondary aim is to assess the outcomes of the intervention at baseline (T0) and post-intervention (T1) (single-arm feasibility design). The study design is primarily based on Bell et al.'s (2018, 2020) blended face-to-face and smartphone intervention for hallucinations. The participants receive four face-to-face therapy sessions, using a smartphone between sessions employing elements of Ecological Momentary Assessment (EMA) and Intervention (EMI).


Clinical Trial Description

The investigators will identify eligible participants at different outpatient departments, suitable support groups, and online platforms. An eligibility screening conducted in person or by telephone to ensure the inclusion criteria and to introduce the study is held by the study assistant. All participants must sign an informed consent after written and verbal study clarification. Participants will carry out self-reported measurements at baseline (T0) and after the intervention phase of 4-6 weeks (T1). The group of participants receives four therapy sessions, using a smartphone between sessions. The intervention begins with a session of psychoeducation, assessment and training, followed by a week of EMA monitoring using the participant's own smartphone or one provided by the research team. In the second session, EMA data will be discussed between therapist and participants to identify patterns in experiences, including effective and ineffective coping strategies. In the weeks between the remaining sessions, participants are reminded of these strategies via the app using EMI. The data management plan includes standard procedures for data-handling such as using anonymized identification codes for patient data. Besides, the participants have the right to access their data, and the right to claim an annihilation. The data is being saved in an online database, only allowing researchers involved in the study to access the data. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06207526
Study type Interventional
Source Charite University, Berlin, Germany
Contact Kerem Böge, PD Dr. Dr.
Phone (+49)30 - 450 517636
Email kerem.boege@charite.de
Status Recruiting
Phase N/A
Start date April 6, 2023
Completion date August 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Active, not recruiting NCT00627029 - Evaluation of Programs of Coordinated Care and Disease Management N/A
Terminated NCT00049738 - Screening for Childhood-Onset Psychotic Disorders N/A
Withdrawn NCT01724372 - The Role of Antidepressants or Antipsychotics in Preventing Psychosis N/A
Completed NCT00716755 - Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. N/A
Completed NCT00498550 - Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Phase 4
Terminated NCT04140773 - The Effect of D-serine as add-on Therapy in Recent-onset Psychosis N/A
Completed NCT01473550 - Mental Health Engagement Network (MHEN) N/A
Completed NCT01207219 - Yoga and Aerobic Exercise in Psychosis N/A
Completed NCT00397033 - Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder. Phase 3
Recruiting NCT04945278 - Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability N/A
Completed NCT03955250 - Mobile After-Care Support App: Pilot RCT N/A
Completed NCT00287352 - Study of Amantadine for Weight Stabilization During Olanzapine Treatment Phase 1
Completed NCT00005658 - Glycine to Treat Psychotic Disorders in Children Phase 2
Terminated NCT00169026 - Alcoholism and Schizophrenia: Effects of Clozapine Phase 4
Completed NCT00001482 - New Drugs in the Treatment of Mood Disorders Phase 2
Terminated NCT03671005 - Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders N/A
Completed NCT00156715 - Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Phase 4
Completed NCT00095524 - Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder Phase 3
Completed NCT03667729 - The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia N/A